Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10410770" target="_blank" >RIV/00216208:11130/20:10410770 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/20:10410770
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=fTXTNPuLJN" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=fTXTNPuLJN</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood.2019003591" target="_blank" >10.1182/blood.2019003591</a>
Alternative languages
Result language
angličtina
Original language name
Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy
Original language description
Children with refractory or relapsed Burkitt lymphoma (BL) or Burkitt leukemia (B-AL) have a poor chance to survive. We describe characteristics, outcome, reinduction, and transplantation approaches and evaluate risk factors among children with progression of a BUB-AL included in Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Miinster studies between 1986 and 2016. Treatment recommendation was reinduction including rituximab from the early 2000s followed by blood stem cell transplantation. The 3-year survival of the 157 children was 18.5 +/- 3%. Survival significantly improved from 11 +/- 3% before to 27 +/- 5% after 2000 (P < .001), allowing for risk factor analyses among the latter 75 patients. Survival of 14 patients with relapse after initial therapy for low-risk disease (R1/R2) was 50 +/- 13% compared with 21 +/- 5% for 61 patients progressing after R3/R4 therapy (P< .02). A total of 25 of 28 patients with progression during first-line therapy, 31 of 32 with progression during reinduction, 15 of 16 not reaching a complete remission (CR) before transplantation, 9 of 10 treated with rituximab front-line, and all 13 patients not receiving rituximab during reinduction died. Forty-six patients received stem cell transplantation (20 autologous, 26 allogeneic). Survival after a regimen combining rituximab with continuous-infusion chemotherapy followed by allogeneic transplantation was 67 +/- 12% compared with 18 +/- 5% for all other regimen and transplantations (P = .003). Patients with relapsed BL/B-AL have a poor chance to survive after current effective frontline therapies. Progression during initial or reinduction chemotherapy and initial high-risk disease are risk factors in relapse. Time-condensed continuous-infusion reinduction followed by stem cell transplantation forms the basis for testing new drugs.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood
ISSN
0006-4971
e-ISSN
—
Volume of the periodical
135
Issue of the periodical within the volume
14
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
1124-1132
UT code for WoS article
000523344000011
EID of the result in the Scopus database
2-s2.0-85079816687